Covid-19: Has the spread of omicron BA.2 made antibody treatments redundant?
The US Food and Drug Administration has removed its authorisation for anti-SARS-CoV-2 monoclonal antibody treatment sotrovimab because of concerns that it is ineffective against the omicron…
